Molina Healthcare (MOH) Q4 2025 earnings review
Q4 Loss Caps a Brutal Year as Medical Costs Outrun Rates
Molina posted a Q4 adjusted loss of $2.75 per share on $10.7B in premium revenue, driven by $2/share of retroactive California Medicaid items and persistent Medicare/Marketplace cost pressure. Full-year adjusted EPS collapsed to $11.03, down 51% from $22.65 in 2024, on premium revenue of $43.1B (+11% YoY). The 2026 outlook is sobering: adjusted EPS guidance of at least $5.00 on ~$42B revenue implies the earnings trough is still ahead. Management frames 2026 as the bottom of the Medicaid margin cycle, with $11+/share in embedded earnings and rate restoration as the path to recovery.
🐂 Bull Case
New store embedded earnings now exceed $11/share, up from $8.65 at Q3, driven by the Florida CMS contract ($4.50/share). This represents over 2x the 2026 guided earnings and provides a clear multi-year earnings bridge once margins normalize.
Every 100 bps of Medicaid MCR improvement translates to ~$5/share in EPS on a $33B premium base. With the market estimated to be 300-400 bps underfunded, even partial rate restoration could double or triple current earnings within 2-3 years.
🐻 Bear Case
2025 adjusted EPS of $11.03 vs. initial guidance of $24.50 represents a 55% miss. The preliminary 2026 outlook of ~$14 given at Q3 has already been cut to $5.00 before a single quarter of 2026 has been reported. The pattern of large, serial downgrades erodes forecasting credibility.
Operating cash flow turned negative at -$535M in 2025 vs. +$644M in 2024. Debt rose to 3.7x EBITDA and 49% debt-to-cap, requiring covenant amendments with the bank syndicate. Parent company cash fell to $223M from $445M.
⚖️ Verdict: 🔴🔴
Very Bearish. A third consecutive earnings downgrade, negative operating cash flow, covenant amendments, and a 2026 guide of $5 EPS (vs. initial 2025 guidance of $24.50 just a year ago) signal a company in deep operational distress. The recovery thesis hinges entirely on state rate restoration and new contract ramp-ups, neither of which is in management's control.
Key Themes
Medical Cost Trend Outpacing Rates — 6 Consecutive Quarters
Medicaid medical cost trend reached 7.5% in 2025 vs. 6% in rate increases, a 150 bps gap that persisted all year despite mid-cycle adjustments. Of the 7.5%, management attributes 250 bps to redetermination-related acuity shifts. The full-year Medicaid MCR hit 91.8%, pushing pretax margin to 2.8% — well below the 4-5% long-term target. For 2026, management guides 5% trend vs. 4% rates, still a negative 100 bps gap. Key cost drivers: behavioral health prevalence at 20% (up from 17-18% three years ago) trending at 9%, pharmacy at 13% (top 10 classes at 35%), professional office visits at 16%, and LTSS hours rising. Management's argument that the acuity shift won't recur in 2026 is the critical assumption: if wrong, the MCR gap widens further.
Marketplace Segment Imploded — 99% Q4 MCR
The Marketplace business, just 10% of premium, was responsible for nearly half of the full-year earnings miss. Q4 MCR hit 99.0%, and full-year MCR was 90.6% — a catastrophic deterioration from 75.4% in 2024. This segment swung from a $617M medical margin in 2024 to $423M in 2025 despite premium nearly doubling from $2.5B to $4.5B. For 2026, Molina is executing a dramatic retreat: 30% average price increases, 20% county footprint reduction, and cutting exposure from ~$4.5B to ~$2.2B in premium. The CEO described Marketplace as 'an option that is currently out of the money.'
California Retroactive Items — $135M Hit, Pulled Through to 2026
Two unexpected retroactive actions from California drove $135M (~$2/share) in Q4 losses: (1) a retroactive risk corridor clawback on the undocumented population (~180K members) that underutilized services, and (2) a risk adjustment recalculation in L.A. County due to dramatic membership churn. Critically, management has assumed these same dynamics will recur in 2026, adding 40 bps to the Medicaid MCR guide. The California corridor was possible only because the undocumented program is state-funded and exempt from CMS restrictions on retroactive corridors.
Balance Sheet Under Strain — Covenant Amendments Required
Operating cash flow swung to -$535M from +$644M in 2024, driven by Medicaid risk corridor settlements, tax timing, and lower earnings. Debt climbed to $3.77B (3.7x trailing EBITDA, 49% debt-to-cap), up from $2.92B a year ago. Parent company cash fell to $223M from $445M. Management disclosed it has 'secured an agreement with the bank syndicate to appropriately amend' debt covenants — a clear signal of balance sheet stress at a time when the earnings outlook is still deteriorating.
MAPD Exit — $1B Revenue Abandoned, $1/Share 2026 Drag
Molina will exit the traditional Medicare Advantage Part D product for 2027, writing off approximately $1B in annual premium that 'does not align with its strategic shift to focus exclusively on dual-eligible members.' The MAPD book is contributing a $1/share drag to 2026 guidance. Full-year Medicare MCR was 92.4%, with Q4 hitting 97.5% — essentially uninsurable at current rates. This is a retreat, not a pivot: margins have been negative and worsening.
Florida CMS Contract — $6B Revenue, $4.50/Share Embedded Earnings
Molina won the sole Children's Medical Services contract in Florida, expected to generate $6B in annual run-rate premium starting late 2026. This adds $4.50/share to embedded earnings (now >$11 total). However, the contract inception creates a $1.50/share drag in 2026 due to pre-revenue hiring, new-store MCR inefficiency, and initial reserve builds. This is a 15% revenue addition from a single contract and materially alters the company's long-term earnings trajectory.
RFP Win Rate Remains Exceptional
Molina's 90% renewal win rate ($14B retained) and 80% new-contract win rate ($20B won) continue to be industry-leading. The active pipeline exceeds $50B in new opportunities. Recent wins include Florida CMS, Georgia Medicaid, Texas STAR+CHIP, and Wisconsin LTSS. The current challenging environment is also creating M&A opportunities as smaller plans struggle, with management describing the pipeline as containing 'actionable opportunities' at or near book value.
Medicaid Rate Restoration Is the Core Recovery Thesis
Management argues the Medicaid market is underfunded by 300-400 bps based on statutory filings of all MCOs. The leverage is enormous: every 100 bps of Medicaid MCR improvement = ~$5/share. Key catalysts: (1) states shifting to 2025 cost baselines for rate-setting, which capture the full cost inflection; (2) discrete rating components for LTSS, pharmacy, and behavioral health are highly transparent and actuarially defensible; (3) the 250 bps redetermination acuity shift should not recur. In 2025, Molina received 150 bps of mid-cycle rate relief, demonstrating states' willingness to act.
Serial Guidance Misses Undermine Credibility
The trajectory of 2025 guidance revisions is alarming: initial $24.50 → Q2 cut to $19.00 → Q3 cut to ~$14.00 → actual $11.03. Now the preliminary 2026 outlook of ~$14 has already been cut to $5.00. Each revision was presented as conservative, yet each proved insufficient. The pattern suggests management consistently underestimates the speed and persistence of medical cost inflation.
Redetermination Acuity Shift Fading — But OB3 Looms
Management estimates that low/no-use members have declined by ~5% within the current Medicaid population as a result of redeterminations, meaning the remaining book is operating closer to the mean MCR. This should reduce the trend-inflating acuity shift in 2026. However, the One Big Beautiful Bill introduces work requirements and semiannual redeterminations starting 2027, potentially removing 15-20% of the 1.3M expansion population (~25% of total Medicaid) over 2027-2029. Management estimates 2-4% annual membership impact, calling it manageable.
Medicare in Transition — Pivoting to Duals, Exiting MAPD
The Medicare segment is being restructured: legacy MAPD ($1B in premium, negative margins) will be exited for 2027, while MMP members are transitioning to new FIDE/HIDE integrated dual-eligible products. These new products carry lower first-year margins but are expected to reach target margins in years 2-3. The 2026 Medicare MCR is guided at 94.0% with a -1.7% pretax margin; excluding MAPD, the segment is closer to breakeven. Medicare premium revenue is guided to $6.6B, up from $6.2B.
Other KPIs
Accelerating deterioration. The consolidated MCR rose from 89.2% in Q1 to 90.4% in Q2 to 92.6% in Q3 to 94.6% in Q4 — a steady, relentless climb. Full-year 91.7% vs. 89.1% in 2024. Every segment deteriorated: Medicaid from 90.3% to 91.8%, Medicare from 89.1% to 92.4%, Marketplace from 75.4% to 90.6%. The 2026 guide of 92.6% implies no improvement despite ~$2.3B in Marketplace premium reduction.
Medicaid $32.2B (+5% YoY), Medicare $6.2B (+13%), Marketplace $4.5B (+79%), Other $90M (new). Marketplace drove disproportionate growth but at catastrophic margins. Total premium grew 11% YoY, but medical margin shrank from $4,199M to $3,564M — a 15% decline. Revenue growth without margin is value-destructive.
Reversing. A dramatic swing from +$644M in 2024 and +$1,662M in 2023. The negative cash flow was driven by Medicaid risk corridor settlements (-$591M in amounts due government agencies), tax payment timing, and lower second-half earnings. This is the first negative annual operating cash flow in recent history and coincides with rising debt levels.
Medicaid lost 322K members (-6.6%) to 4.57M due to redeterminations and eligibility tightening. Medicare grew to 262K (+8.3%). Marketplace surged to 655K (+62.5%), though this is set to halve in 2026. Year-end 2026 guided at 5.1M: Medicaid 4.6M (flat with FL CMS offset), Medicare 230K (down due to MAPD exit), Marketplace 220K (-66%).
Guidance
Decelerating sharply. Down 55% from FY25 actual of $11.03, which itself was down 51% from FY24's $22.65. The guide is burdened by $2.50/share: $1.50 from Florida CMS implementation and $1.00 from MAPD underperformance. Underlying earnings are ~$7.50/share. Management identifies three upside levers: Medicaid trend moderation, off-cycle rate adjustments (100 bps = ~$5/share), and Medicare/Marketplace outperformance vs. conservative pricing. Earnings are front-loaded: ~2/3 in H1 due to Medicaid rate cycle and Florida CMS inception in Q4.
Decelerating. Down ~2% from $43.1B in FY25, the first premium revenue decline in years. Medicaid +$1.1B (Florida CMS + modest rate cycle, offset by Virginia loss and market contraction), Medicare +$300M (mix shift to higher-PMPM integrated products, partially offset by MAPD decline), Marketplace -$2.3B (intentional retreat). Does NOT include Georgia Medicaid or Texas STAR+CHIP, now expected in 2027.
Decelerating. MCR up 110 bps from FY25's 91.8%. The 92.9% includes 40 bps from California retro items pulled through and 30 bps from Florida CMS new-store drag. Rates at ~4% vs. 5% trend = continued negative 100 bps gap. Excluding Florida CMS, pretax margin is ~1.6% — still deeply below the 4-5% long-term target.
Decelerating. MCR worsening from 92.4% in FY25 to 94.0%. The negative margin is driven by MAPD underperformance ($1/share burden) and first-year margin dilution from MMP-to-FIDE/HIDE transitions. Excluding MAPD, the segment is closer to breakeven. MAPD exit for 2027 will remove the drag.
Reversing to positive. Premium dropping ~50% from $4.5B, but MCR improving dramatically from 90.6% to a guided 85.5%. The aggressive repricing (30% average increase) and footprint reduction are designed to restore profitability on a much smaller, more predictable book. Renewal members now 70% of the book. End-year membership guided at 220K vs. 655K at YE25. SEP enrollment expected to be significantly lower.
No specific cash flow guidance was provided. Given guided net income of $164M (GAAP), the swing from -$535M in OCF in 2025 should moderate as corridor settlements normalize. However, the low earnings base and Florida CMS implementation costs suggest free cash flow will remain under pressure.
Key Questions
Medicaid Trend Assumption Credibility
You guided 4.5% Medicaid trend in initial 2025 guidance and actual came in at 7.5%. Now you guide 5% for 2026. What gives you confidence this won't repeat, especially given pharmacy and behavioral health trends you cited at 13% and 18% respectively?
Covenant Amendment Details
You disclosed that debt covenants required amendment with the bank syndicate. What are the new covenant terms? At what point does the balance sheet constrain your ability to fund Florida CMS implementation and pursue M&A?
Embedded Earnings Realization Timeline
Embedded earnings grew from $7.75 to $11+/share, but 2026 only harvests $0.60. Given the current margin environment, what is the realistic timeline for realizing the remaining ~$10.40, and what margin environment must exist for these to reach target returns?
Florida CMS Execution Risk
A $6B sole-source contract for high-acuity children is an enormous undertaking. What is your staffing plan, how many members do you expect at inception, and what is the MCR assumption for the initial quarter that drives the $1.50/share drag?
Share Repurchase Pause
No buybacks were discussed for 2026, and the share count is guided flat at 51.1M. With parent cash at $223M, debt at 3.7x EBITDA, and negative operating cash flow, is the buyback program effectively suspended?